Hospira Begins Phase I U.S. Clinical Trial Of Biosimilar Erythropoietin In Renal Patients
Links shared publicly online about this topic.
- 988total visits
Hospira Begins Phase I U.S. Clinical Trial Of Biosimilar Erythropoietin In Renal Patients
View full resource at medicalnewstoday.com
Tags: Anemia Medication, Kidney Health, Clinical Trial, Procrit, Eprex, Epogen, NeoRecormon, Epogin
Most Recently Shared on July 29, 2010 at 1:05 am By:
Hospira Begins Phase I U.S. Clinical Trial Of Biosimilar Erythropoietin In Renal Patients: Hospira, Inc. (NYSE: HS... http://mnt.to/f/3GHt
Also Shared By:
Hospira commences EPO Phase I U.S. clinical trial in renal dysfunction patients with anemia
news-medical.net — “Hospira, Inc., the world leader in generic injectable pharmaceuticals, today announced the start of a U.S. Phase I clinical trial of its biosimilar erythropoietin (EPO) in patients with renal (kidney) dysfunction who have anemia, an important step on the road toward introducing a biosimilar product in the United States. Erythropoietin is a treatment for anemia associated with chronic renal failure and chemotherapy.” View full resource at news-medical.net
Most Recently Shared on July 26, 2010 at 4:25 pm By:
Hospira commences EPO Phase I U.S. clinical trial in renal dysfunction patients with anemia: Hospira, Inc., the wo... http://bit.ly/9Cc6b1
Advertisement
medical_tweets
@medical_tweets
Hospira Begins Phase I U.S. Clinical Trial Of Biosimilar Erythropoietin In Renal Patients Hospira, Inc. (NYSE: HSP), th.. http://dld.bz/pfYy
1 year ago...